No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab

Leuk Lymphoma. 2016 Nov;57(11):2705-8. doi: 10.3109/10428194.2016.1157877. Epub 2016 Apr 15.

Authors

Christina Kalpadakis¹, Gerassimos A Pangalis², Sotirios Sachanas², Demetra Rontogianni³, Penelope Korkolopoulou⁴, Vassilis Milionis⁴, Theodoros P Vassilakopoulos⁵, Helen A Papadaki¹, Maria K Angelopoulou⁵

Affiliations

¹ a Department of Haematology , Heraklion University Hospital, University of Crete , Crete , Greece ;
² b Department of Haematology , Athens Medical Center-Psychikon Branch , Athens , Greece ;
³ c Department of Anatomic Pathology , Evangelismos General Hospital , Athens , Greece ;
⁴ d Department of Pathology , University of Athens , Athens , Greece ;
⁵ e Department of Haematology , National and Kapodistrian University of Athens, Laikon General Hospital , Athens , Greece.

PMID: 27082039
DOI: 10.3109/10428194.2016.1157877

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / etiology
Anemia, Hemolytic, Autoimmune / surgery*
Female
Humans
Lymphoma, B-Cell, Marginal Zone / complications
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Lymphoma, B-Cell, Marginal Zone / pathology
Lymphoma, B-Cell, Marginal Zone / surgery*
Male
Middle Aged
Rituximab / therapeutic use*
Splenectomy
Splenic Neoplasms / complications
Splenic Neoplasms / drug therapy*
Splenic Neoplasms / pathology
Splenic Neoplasms / surgery*
Treatment Outcome

Substances

Rituximab